Literature DB >> 28940520

Direction modulated brachytherapy (DMBT) for treatment of cervical cancer: A planning study with 192 Ir, 60 Co, and 169 Yb HDR sources.

Habib Safigholi1, Dae Yup Han2, Shahram Mashouf1, Abraam Soliman1, Ali S Meigooni3, Amir Owrangi4, William Y Song1,5.   

Abstract

PURPOSE: To evaluate plan quality of a novel MRI-compatible direction modulated brachytherapy (DMBT) tandem applicator using 192 Ir, 60 Co, and 169 Yb HDR brachytherapy sources, for various cervical cancer high-risk clinical target volumes (CTVHR ).
MATERIALS AND METHODS: The novel DMBT tandem applicator has six peripheral grooves of 1.3-mm diameter along a 5.4-mm thick nonmagnetic tungsten alloy rod. Monte Carlo (MC) simulations were used to benchmark the dosimetric parameters of the 192 Ir, 60 Co, and 169 Yb HDR sources in a water phantom against the literature data. 45 clinical cases that were treated using conventional tandem-and-ring applicators with 192 Ir source (192 Ir-T&R) were selected consecutively from intErnational MRI-guided BRAchytherapy in CErvical cancer (EMBRACE) trial. Then, for each clinical case, 3D dose distribution of each source inside the DMBT and conventional applicators were calculated and imported onto an in-house developed inverse planning optimization code to generate optimal plans. All plans generated by the DMBT tandem-and-ring (DMBT T&R) from all three sources were compared to the respective 192 Ir-T&R plans. For consistency, all plans were normalized to the same CTVHR D90 achieved in clinical plans. The D2 cm3 for organs at risk (OAR) such as bladder, rectum, and sigmoid, and D90, D98, D10, V100, and V200 for CTVHR were calculated.
RESULTS: In general, plan quality significantly improved when a conventional tandem (Con.T) is replaced with the DMBT tandem. The target coverage metrics were similar across 192 Ir-T&amp;R and DMBT T&amp;R plans with all three sources (P > 0.093). 60 Co-DMBT T&amp;R generated greater hot spots and less dose homogeneity in the target volumes compared with the 192 Ir- and 169 Yb-DMBT T&amp;R plans. Mean OAR doses in the DMBT T&amp;R plans were significantly smaller (P < 0.0084) than the 192 Ir-T&amp;R plans. Mean bladder D2 cm3 was reduced by 4.07%, 4.15%, and 5.13%, for the 192 Ir-, 60 Co-, and 169 Yb-DMBT T&amp;R plans respectively. Mean rectum (sigmoid) D2 cm3 was reduced by 3.17% (3.63%), 2.57% (3.96%), and 4.65% (4.34%) for the 192 Ir-, 60 Co-, and 169 Yb-DMBT T&amp;R plans respectively. The DMBT T&amp;R plans with the 169 Yb source generally resulted in the greatest OAR sparing when the CTVHR were larger and irregular in shape, while for smaller and regularly shaped CTVHR (<30 cm3 ), OAR sparing between the sources were comparable.
CONCLUSIONS: The DMBT tandem provides a promising alternative to the Con.T design with significant improvement in the plan quality for various target volumes. The DMBT T&amp;R plans generated with the three sources of varying energies generated superior plans compared to the conventional T&amp;R applicators. Plans generated with the 169 Yb-DMBT T&amp;R produced best results for larger and irregularly shaped CTVHR in terms of OAR sparing. Thus, this study suggests that the combination of the DMBT tandem applicator with varying energy sources can work synergistically to generate improved plans for cervical cancer brachytherapy.
© 2017 American Association of Physicists in Medicine.

Entities:  

Keywords:  169Yb; 192Ir; 60Co; cervical cancer; direction modulated brachytherapy

Mesh:

Substances:

Year:  2017        PMID: 28940520     DOI: 10.1002/mp.12598

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  Needle-free cervical cancer treatment using helical multishield intracavitary rotating shield brachytherapy with the 169 Yb Isotope.

Authors:  Karolyn M Hopfensperger; Quentin Adams; Yusung Kim; Xiaodong Wu; Weiyu Xu; Kaustubh Patwardhan; Bounnak Thammavong; Joseph Caster; Ryan T Flynn
Journal:  Med Phys       Date:  2020-03-13       Impact factor: 4.071

2.  Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.

Authors:  Quentin Adams; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Weiyu Xu; Hemant Shukla; James McGee; Joseph M Caster; Ryan T Flynn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-06       Impact factor: 7.038

3.  Efficient 169 Yb high-dose-rate brachytherapy source production using reactivation.

Authors:  Ryan T Flynn; Quentin E Adams; Karolyn M Hopfensperger; Xiaodong Wu; Weiyu Xu; Yusung Kim
Journal:  Med Phys       Date:  2019-05-27       Impact factor: 4.071

4.  HDR brachytherapy in vivo source position verification using a 2D diode array: A Monte Carlo study.

Authors:  Joel Poder; Dean Cutajar; Susanna Guatelli; Marco Petasecca; Andrew Howie; Joseph Bucci; Anatoly Rosenfeld
Journal:  J Appl Clin Med Phys       Date:  2018-06-01       Impact factor: 2.102

5.  High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option.

Authors:  Rajendra Bhalavat; Vibhay Pareek; Manish Chandra; Lalitha Nellore; Karishma George; Dipalee Borade; Ketan Kalariya; Zaiba Moosa; Amrita Srivastava; Navaneeth Reddy; Ankita Kapoor; Darshana Kawale; Nandakumar P; Pratibha Bauskar
Journal:  J Contemp Brachytherapy       Date:  2018-10-15

Review 6.  Evolution of Brachytherapy Applicators for the Treatment of Cervical Cancer.

Authors:  Ankur Mourya; Lalit Mohan Aggarwal; Sunil Choudhary
Journal:  J Med Phys       Date:  2021-12-31

7.  A comparative assessment of inhomogeneity and finite patient dimension effects in 60Co and 192Ir high-dose-rate brachytherapy.

Authors:  Irina Fotina; Kyveli Zourari; Vasileios Lahanas; Evaggelos Pantelis; Panagiotis Papagiannis
Journal:  J Contemp Brachytherapy       Date:  2018-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.